Immunotoxin Market Report 2026

The immunotoxin market size has grown strongly in recent years. It will grow from $66 billion in 2025 to $71.71 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to early success of antibody-toxin conjugates in cancer research, advancements in monoclonal antibody engineering, unmet need for targeted cancer therapies, expansion of oncology-focused research laboratories, increased understanding of tumor-specific antigens.

The immunotoxin market size is expected to see strong growth in the next few years. It will grow to $96.77 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growing demand for precision oncology treatments, expansion of immunotherapy pipelines, increasing investment in biologics-based cancer drugs, rising prevalence of treatment-resistant cancers, continued innovation in protein engineering technologies. Major trends in the forecast period include rising development of target-specific immunotoxins for cancer therapy, growing focus on reducing off-target toxicity and immunogenicity, increasing use of immunotoxins in hematological malignancies, expansion of clinical research in next-generation immunotoxin constructs, continued exploration of combination immunotoxin therapies.

The rising incidence of breast cancer is expected to drive the growth of the immunotoxin market in the coming years. Breast cancer is a malignant disease that originates in the cells of the breast, most often in the ducts or lobules. The occurrence of breast cancer is increasing due to factors such as improved screening programs, lifestyle-related risk factors, and longer life expectancy. The immunotoxin market supports breast cancer treatment by offering targeted therapies that selectively destroy cancer cells while limiting damage to healthy tissues, thereby reducing side effects compared with conventional chemotherapy. For example, in January 2025, according to the National Breast Cancer Foundation, a US-based organization, one in eight women in the United States is expected to be diagnosed with breast cancer during her lifetime. In 2024, an estimated 310,720 women and 2,800 men are projected to be diagnosed with invasive breast cancer. Therefore, the growing incidence of breast cancer is fueling the expansion of the immunotoxin market.

Major companies operating in the immunotoxin market are concentrating on the development of advanced antibody-drug conjugates (ADCs) to improve the precision and effectiveness of cancer treatments while minimizing harm to healthy tissues. ADCs are targeted biopharmaceutical therapies made up of a monoclonal antibody linked to a cytotoxic drug, allowing accurate delivery of the toxic agent to cancer cells that express specific antigens and enhancing treatment outcomes compared with traditional chemotherapy. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical company, and Genmab A/S, a Denmark-based biotechnology company, received full approval from the U.S. Food and Drug Administration for TIVDAK, an antibody-drug conjugate developed for patients with metastatic or recurrent cervical cancer. This therapy uses a monomethyl auristatin E payload that disrupts microtubules to trigger cancer cell death and has demonstrated statistically significant improvements in overall survival, positioning it as a promising targeted option for advanced cervical cancer.

In February 2024, AbbVie, a US-based biopharmaceutical company, acquired ImmunoGen Inc. for an undisclosed amount. This acquisition strengthens AbbVie’s oncology portfolio by incorporating ImmunoGen’s advanced antibody-drug conjugate technology to support the development of targeted cancer therapies. It also enhances AbbVie’s position in next-generation oncology treatments by expanding its pipeline with clinically validated ADC assets. ImmunoGen Inc. is a US-based biotechnology company that develops immunotoxins.

Major companies operating in the immunotoxin market are ImmunoGen Inc., Molecular Templates Inc., Mersana Therapeutics, Seagen Inc., MacroGenics Inc., Sutro Biopharma Inc., Celldex Therapeutics, CytImmune Sciences Inc., Pfizer Inc., Roche Holding AG, AbbVie Inc., Bristol Myers Squibb, AstraZeneca plc, Merck KGaA, BioNTech SE, Ipsen Pharma, Innate Pharma Inc., GenScript, Thermo Fisher Scientific Inc., Enzo Life Sciences Inc.

North America was the largest region in the immunotoxin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunotoxin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunotoxin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the immunotoxin market by increasing the cost of imported biologic raw materials, specialized toxins, and biomanufacturing equipment required for protein conjugation and formulation. These effects have been most pronounced in research-intensive and early-stage clinical segments, particularly in North America and Europe where complex biologics supply chains rely on cross-border sourcing. Asia-Pacific regions have experienced procurement delays due to regulatory and trade barriers. However, tariffs have encouraged localized biologics manufacturing and regional research collaborations, supporting long-term supply chain resilience.

The immunotoxin market research report is one of a series of new reports that provides immunotoxin market statistics, including immunotoxin industry global market size, regional shares, competitors with a immunotoxin market share, detailed immunotoxin market segments, market trends and opportunities, and any further data you may need to thrive in the immunotoxin industry. This immunotoxin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Immunotoxins are engineered proteins that link an antibody or antibody fragment to a toxin, enabling the selective targeting and destruction of specific cells, such as cancer cells. The antibody component binds to a particular antigen on the surface of the target cell, allowing the toxin to be delivered directly into the cell. Immunotoxins are designed to minimize damage to healthy cells and tissues, thereby reducing side effects compared with conventional chemotherapy.

The primary types of immunotoxins include anthrax-based toxins, diphtheria toxin (DT) and its derivatives, pseudomonas exotoxin (PE) and its derivatives, ribosome-inactivating protein-based immunotoxins, ribonuclease-based immunotoxins, and others. Anthrax-based toxins are compounds produced by bacteria that cause anthrax, a serious disease. These immunotoxins are used in a range of applications, including solid tumors, leukemias, and others, and are utilized by various end users such as hospitals and clinics, cancer and radiation therapy centers, research laboratories, and others.

The immunotoxin market consists of sales of linker molecules, expression systems, antibody or antibody fragments, and cytotoxic agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.